NCT03078699

Prospective Study of Stereotactic Body Radiation Therapy for Thymoma Inoma: Therapeutic Effect and Toxicity Assessment

Completed NA Last updated 13 March 2017

What this trial tests

NA trial testing stereotactic body radiation therapy in Thymoma in 32 participants. Completed in 1 September 2016.

Timeline

1 January 2005

Primary endpoint
1 January 2014

1 September 2016

Quick facts

Lead sponsor	Third Military Medical University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	32
Start date	1 January 2005
Primary completion	1 January 2014
Estimated completion	1 September 2016
Sites	1 location across China

Drugs / interventions tested

• stereotactic body radiation therapy — full drug profile →

Conditions studied

• Thymoma — all drugs for Thymoma →
• Thymic Tumor — all drugs for Thymic Tumor →

Sponsor

Third Military Medical University

Who can join

Adults 18 to 75, any sex, with Thymoma or Thymic Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

For patients with unresectable or recurrent disease, radiation is routinely administered, often in combination with systemic chemotherapy. However, because of wide range of radiation, more complications of conventional radiotherapy limit its treatment dose. The local recurrence rates of conventional radiotherapy are dissatisfied.Stereotactic body radiation therapy(SBRT) well solved the problem above. On the one hand, by improving the single dose, it not only shortens the total radiation treatment, but also increases the total dose of equivalent biological effects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Prospective Study of Stereotactic Body Radiation Therapy for Thymoma and Thymic Carcinoma: Therapeutic Effect and Toxicity Assessment.
   Hao XJ, Peng B, Zhou Z, Yang XQ. · · 2017 · cited 13× · PMID 29051511 · DOI 10.1038/s41598-017-12909-z